The University of Southampton
University of Southampton Institutional Repository

Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma

Rao, S., Watkins, D., Cunningham, D., Dunlop, D., Johnson, P., Selby, P., Hancock, B.W., Fegan, C., Culligan, D., Schey, S., Morris, T.C.M., Lissitchkov, T., Oliver, J.W. and Holmlund, J.T. (2004) Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma Annals of Oncology, 15, (9), pp. 1413-1418. (doi:10.1093/annonc/mdh359).

Record type: Article

Abstract

Background: The purpose of this study was to assess the efficacy and safety of ISIS 3521, an antisense phosphorothioate oligonucleotide to protein kinase C {alpha} in patients with relapsed low-grade non-Hodgkin's lymphoma (NHL).
Patients and methods: Twenty-six patients received ISIS 3521 (2 mg/kg/day) as a continuous infusion over 21 days of each 28-day cycle.
Results: The median age of the patients was 53 years (range 37–77). Histological subtypes were low-grade follicular lymphoma (n=22) and B-cell small lymphocytic lymphoma (n=4). Twenty-one (81%) had stage III/IV disease. The median number of previous lines of chemotherapy was two (range one to six). A total of 87 cycles of ISIS 3521 were administered. Twenty-three patients were assessable for response. Three patients achieved a partial response. No complete responses were observed. Ten patients had stable disease. Grade 3–4 toxicity was as follows: neutropenia (3.8%) and thrombocytopenia (26.9%).
Conclusions: ISIS 3521 has demonstrated anti-tumour activity in patients with relapsed low-grade NHL. There may be a potential role for this agent in combination with conventional chemotherapy for advanced low-grade lymphoma, and further trials are warranted.

Full text not available from this repository.

More information

Published date: 2004
Additional Information: ISI:000223868600015
Keywords: antisense, follicular, non-Hodgkin's lymphoma, treatment
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 26552
URI: http://eprints.soton.ac.uk/id/eprint/26552
ISSN: 0923-7534
PURE UUID: aacb6e42-07b0-4225-8eb6-f8773c2cfa5b
ORCID for P. Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 20 Apr 2006
Last modified: 17 Jul 2017 16:07

Export record

Altmetrics

Contributors

Author: S. Rao
Author: D. Watkins
Author: D. Cunningham
Author: D. Dunlop
Author: P. Johnson ORCID iD
Author: P. Selby
Author: B.W. Hancock
Author: C. Fegan
Author: D. Culligan
Author: S. Schey
Author: T.C.M. Morris
Author: T. Lissitchkov
Author: J.W. Oliver
Author: J.T. Holmlund

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×